Using a genetic/clinical risk score to stop smoking (GeTSS): randomised controlled trial
Abstract Background As genetic tests become cheaper, the possibility of their widespread availability must be considered. This study involves a risk score for lung cancer in smokers that is roughly 50% genetic (50% clinical criteria). The risk score has been shown to be effective as a smoking cessat...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-10-01
|
Series: | BMC Research Notes |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13104-017-2831-2 |
id |
doaj-7fac0dde7f7a428696afd2da2845ae8a |
---|---|
record_format |
Article |
spelling |
doaj-7fac0dde7f7a428696afd2da2845ae8a2020-11-25T02:53:08ZengBMCBMC Research Notes1756-05002017-10-011011910.1186/s13104-017-2831-2Using a genetic/clinical risk score to stop smoking (GeTSS): randomised controlled trialJohn A. A. Nichols0Paul Grob1Wendy KitePeter Williams2Simon de Lusignan3Department of Clinical and Experimental Medicine, University of SurreyDepartment of Clinical and Experimental Medicine, University of SurreyDepartment of Mathematics, University of SurreyDepartment of Clinical and Experimental Medicine, University of SurreyAbstract Background As genetic tests become cheaper, the possibility of their widespread availability must be considered. This study involves a risk score for lung cancer in smokers that is roughly 50% genetic (50% clinical criteria). The risk score has been shown to be effective as a smoking cessation motivator in hospital recruited subjects (not actively seeking cessation services). Methods This was an RCT set in a United Kingdom National Health Service (NHS) smoking cessation clinic. Smokers were identified from medical records. Subjects that wanted to participate were randomised to a test group that was administered a gene-based risk test and given a lung cancer risk score, or a control group where no risk score was performed. Each group had 8 weeks of weekly smoking cessation sessions involving group therapy and advice on smoking cessation pharmacotherapy and follow-up at 6 months. The primary endpoint was smoking cessation at 6 months. Secondary outcomes included ranking of the risk score and other motivators. Results 67 subjects attended the smoking cessation clinic. The 6 months quit rates were 29.4%, (10/34; 95% CI 14.1–44.7%) for the test group and 42.9% (12/28; 95% CI 24.6–61.2%) for the controls. The difference is not significant. However, the quit rate for test group subjects with a “very high” risk score was 89% (8/9; 95% CI 68.4–100%) which was significant when compared with the control group (p = 0.023) and test group subjects with moderate risk scores had a 9.5% quit rate (2/21; 95% CI 2.7–28.9%) which was significantly lower than for above moderate risk score 61.5% (8/13; 95% CI 35.5–82.3; p = 0.03). Conclusions Only the sub-group with the highest risk score showed an increased quit rate. Controls and test group subjects with a moderate risk score were relatively unlikely to have achieved and maintained non-smoker status at 6 months. ClinicalTrials.gov ID NCT01176383 (date of registration: 3 August 2010)http://link.springer.com/article/10.1186/s13104-017-2831-2Smoking cessationGenetic testingLung neoplasmsPrimary health care |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
John A. A. Nichols Paul Grob Wendy Kite Peter Williams Simon de Lusignan |
spellingShingle |
John A. A. Nichols Paul Grob Wendy Kite Peter Williams Simon de Lusignan Using a genetic/clinical risk score to stop smoking (GeTSS): randomised controlled trial BMC Research Notes Smoking cessation Genetic testing Lung neoplasms Primary health care |
author_facet |
John A. A. Nichols Paul Grob Wendy Kite Peter Williams Simon de Lusignan |
author_sort |
John A. A. Nichols |
title |
Using a genetic/clinical risk score to stop smoking (GeTSS): randomised controlled trial |
title_short |
Using a genetic/clinical risk score to stop smoking (GeTSS): randomised controlled trial |
title_full |
Using a genetic/clinical risk score to stop smoking (GeTSS): randomised controlled trial |
title_fullStr |
Using a genetic/clinical risk score to stop smoking (GeTSS): randomised controlled trial |
title_full_unstemmed |
Using a genetic/clinical risk score to stop smoking (GeTSS): randomised controlled trial |
title_sort |
using a genetic/clinical risk score to stop smoking (getss): randomised controlled trial |
publisher |
BMC |
series |
BMC Research Notes |
issn |
1756-0500 |
publishDate |
2017-10-01 |
description |
Abstract Background As genetic tests become cheaper, the possibility of their widespread availability must be considered. This study involves a risk score for lung cancer in smokers that is roughly 50% genetic (50% clinical criteria). The risk score has been shown to be effective as a smoking cessation motivator in hospital recruited subjects (not actively seeking cessation services). Methods This was an RCT set in a United Kingdom National Health Service (NHS) smoking cessation clinic. Smokers were identified from medical records. Subjects that wanted to participate were randomised to a test group that was administered a gene-based risk test and given a lung cancer risk score, or a control group where no risk score was performed. Each group had 8 weeks of weekly smoking cessation sessions involving group therapy and advice on smoking cessation pharmacotherapy and follow-up at 6 months. The primary endpoint was smoking cessation at 6 months. Secondary outcomes included ranking of the risk score and other motivators. Results 67 subjects attended the smoking cessation clinic. The 6 months quit rates were 29.4%, (10/34; 95% CI 14.1–44.7%) for the test group and 42.9% (12/28; 95% CI 24.6–61.2%) for the controls. The difference is not significant. However, the quit rate for test group subjects with a “very high” risk score was 89% (8/9; 95% CI 68.4–100%) which was significant when compared with the control group (p = 0.023) and test group subjects with moderate risk scores had a 9.5% quit rate (2/21; 95% CI 2.7–28.9%) which was significantly lower than for above moderate risk score 61.5% (8/13; 95% CI 35.5–82.3; p = 0.03). Conclusions Only the sub-group with the highest risk score showed an increased quit rate. Controls and test group subjects with a moderate risk score were relatively unlikely to have achieved and maintained non-smoker status at 6 months. ClinicalTrials.gov ID NCT01176383 (date of registration: 3 August 2010) |
topic |
Smoking cessation Genetic testing Lung neoplasms Primary health care |
url |
http://link.springer.com/article/10.1186/s13104-017-2831-2 |
work_keys_str_mv |
AT johnaanichols usingageneticclinicalriskscoretostopsmokinggetssrandomisedcontrolledtrial AT paulgrob usingageneticclinicalriskscoretostopsmokinggetssrandomisedcontrolledtrial AT wendykite usingageneticclinicalriskscoretostopsmokinggetssrandomisedcontrolledtrial AT peterwilliams usingageneticclinicalriskscoretostopsmokinggetssrandomisedcontrolledtrial AT simondelusignan usingageneticclinicalriskscoretostopsmokinggetssrandomisedcontrolledtrial |
_version_ |
1724726566671351808 |